JP2006518750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518750A5 JP2006518750A5 JP2006503763A JP2006503763A JP2006518750A5 JP 2006518750 A5 JP2006518750 A5 JP 2006518750A5 JP 2006503763 A JP2006503763 A JP 2006503763A JP 2006503763 A JP2006503763 A JP 2006503763A JP 2006518750 A5 JP2006518750 A5 JP 2006518750A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functionally equivalent
- inhibitor
- fragment
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 14
- 239000004074 complement inhibitor Substances 0.000 claims 7
- 229940124073 Complement inhibitor Drugs 0.000 claims 6
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims 2
- 108010009575 CD55 Antigens Proteins 0.000 claims 2
- 108010027437 compstatin Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229940123362 C1Q inhibitor Drugs 0.000 claims 1
- -1 C1q inhibitor Proteins 0.000 claims 1
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 claims 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 102000003780 Clusterin Human genes 0.000 claims 1
- 108090000197 Clusterin Proteins 0.000 claims 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 102100031673 Corneodesmosin Human genes 0.000 claims 1
- 101710139375 Corneodesmosin Proteins 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 108010085169 Lysine carboxypeptidase Proteins 0.000 claims 1
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims 1
- 102000050019 Membrane Cofactor Human genes 0.000 claims 1
- 101710146216 Membrane cofactor protein Proteins 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44904503P | 2003-02-21 | 2003-02-21 | |
| PCT/US2004/005143 WO2004075838A2 (en) | 2003-02-21 | 2004-02-20 | Method and compositions for the treatment of meconium aspiration syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518750A JP2006518750A (ja) | 2006-08-17 |
| JP2006518750A5 true JP2006518750A5 (https=) | 2007-04-12 |
Family
ID=32927491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503763A Pending JP2006518750A (ja) | 2003-02-21 | 2004-02-20 | 胎便吸引症候群の治療のための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070065433A1 (https=) |
| EP (1) | EP1594541A4 (https=) |
| JP (1) | JP2006518750A (https=) |
| WO (1) | WO2004075838A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019326A1 (en) * | 2003-06-16 | 2005-01-27 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| ES2432112T3 (es) * | 2004-02-10 | 2013-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados |
| CA2610340C (en) * | 2005-05-26 | 2016-02-16 | Vernon Michael Holers | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| PL2148691T3 (pl) * | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
| CA2680344A1 (en) | 2007-03-14 | 2008-11-20 | Woodruff Emlen | Humaneered anti-factor b antibody |
| ATE537833T1 (de) | 2007-06-21 | 2012-01-15 | Pantarhei Bioscience Bv | Behandlung des mekoniumaspirationssyndroms mit östrogenen |
| CN102316790A (zh) * | 2007-10-16 | 2012-01-11 | 堤乐哈修门医学研究基础建设及服务有限公司 | 羊水中胎粪鉴定装置及方法 |
| WO2010034015A2 (en) * | 2008-09-22 | 2010-03-25 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| PE20150159A1 (es) | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
| EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
| ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| JP2020516607A (ja) | 2017-04-07 | 2020-06-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| AU2018386304B2 (en) | 2017-12-15 | 2023-12-07 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| EP4153237A4 (en) * | 2020-05-21 | 2024-07-03 | EyePoint Pharmaceuticals, Inc. | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH TIE-2 ACTIVATORS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6013619A (en) * | 1988-01-06 | 2000-01-11 | The Scripps Research Institute | Pulmonary surfactants and therapeutic uses, including pulmonary lavage |
| US5514598A (en) * | 1993-11-30 | 1996-05-07 | Doody; Michael | Prenatal detection of meconium |
| US5562077B1 (en) * | 1995-04-04 | 2000-09-05 | Joseph Schultz | Method and apparatus for ventilation and aspiration |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6044284A (en) * | 1998-10-08 | 2000-03-28 | Leonard I. Eisenfeld | Apparatus and method for measuring the concentration of meconium in amniotic fluid |
| EP1152759A2 (en) * | 1999-02-09 | 2001-11-14 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| JP2001089391A (ja) * | 1999-09-16 | 2001-04-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Ｉｒｄｓおよびａｌｉの治療用の製薬的組成物、その使用、およびそれを有する製品 |
| NZ526720A (en) * | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
-
2004
- 2004-02-20 EP EP04713391A patent/EP1594541A4/en not_active Withdrawn
- 2004-02-20 US US10/546,253 patent/US20070065433A1/en not_active Abandoned
- 2004-02-20 JP JP2006503763A patent/JP2006518750A/ja active Pending
- 2004-02-20 WO PCT/US2004/005143 patent/WO2004075838A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006518750A5 (https=) | ||
| US7183381B2 (en) | Composition of lactoferrin related peptides and uses thereof | |
| US10945962B2 (en) | Controlled-release peptide compositions and uses thereof | |
| JP2018052983A5 (https=) | ||
| JP2009528369A (ja) | 補体活性を抑制することによる同種移植片の生存の延長 | |
| JP2011518179A5 (https=) | ||
| Lalani et al. | Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease | |
| JP2005515214A5 (https=) | ||
| JP2008518090A5 (https=) | ||
| JP2023510864A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の肺疾患の治療的使用 | |
| JP2011522864A5 (https=) | ||
| US20230151107A1 (en) | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 | |
| JP2005511504A5 (https=) | ||
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| Ayala et al. | Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis | |
| WO2015104596A1 (en) | Vasoactive intestinal peptide | |
| Huang et al. | Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41 | |
| JP2007500693A (ja) | 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法 | |
| EP3356389A1 (en) | Use of human derived immunosuppressive proteins and peptides as medicaments | |
| US7494975B2 (en) | Anti-HIV composition, production method thereof and medicament | |
| JP2010511706A5 (https=) | ||
| CN1685064A (zh) | 用于预防和治疗获得性免疫缺陷综合症的协同组合物 | |
| CN106539813B (zh) | 干扰素刺激基因(sting)激活剂在抗炎症中的应用 | |
| EP3541407A1 (en) | Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes | |
| JP2000506839A (ja) | 天然ヒトα―インターフェロンを含む薬剤組成物 |